US FDA drafts 5-yr plan to strengthen e-submission of drug applications, data
This article was originally published in SRA
The US Food and Drug Administration is inviting feedback on a range of IT-related initiatives that it plans to undertake over the next five years to support the review of prescription and generic drug applications1,2. Among other things, the agency plans to implement by June 2014 certain changes to the electronic common technical document or eCTD that is used by drug companies for making regulatory submissions.
You may also be interested in...
Canada joins other international regulators in announcing plans to implement the next major revision of the electronic common technical document format (eCTD v4). A roadmap has been issued to help pharmaceutical companies prepare and plan for this change.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.